About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025.

After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and delivering value to patients, partners, and investors.

Anthony Amato, CEO of Ocuvex, commented: "The decision to mutually terminate the merger agreement does not impact Ocuvex’s momentum or our commitment to patients. We are excited to announce that Ocuvex has received its New Jersey state pharmaceutical license, and the commercial launch of Omlonti will commence in the coming weeks. Our pipeline continues to advance, and we remain focused on delivering innovative ophthalmic solutions to the market."

Andrew Oakley, Chairman of the Board of Onconetix, added: "Ocuvex is an innovative company with a strong commitment to advancing eye health. Despite our decision to part ways, we are confident that Omlonti will deliver value for patients and the ophthalmic community upon launch and future growth."

Both organizations express appreciation for the collaborative spirit and professionalism shown throughout the merger discussions.

About Onconetix, Inc.
Onconetix (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. Through its acquisition of Proteomedix, Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR. For more information, visit www.onconetix.com.

About Ocuvex Therapeutics, Inc.
Ocuvex is dedicated to advancing ophthalmic science and improving patient outcomes through innovative research and product development. For more information, visit www.ocuvextherapeutics.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to various risks and uncertainties. Please refer to each company’s filings with the Securities and Exchange Commission for more information.

Contact Information:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Investor Relations: investors@onconetix.com

Ocuvex Therapeutics, Inc.
1 Bridge Plaza, 2nd Floor

Fort Lee, NJ 07024

Phone:  551-258-2635

Investor Relations: info@ocuvextherapeutics.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.